O’Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated ...

TORONTO--(BUSINESS WIRE)--Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, announced today the release of the manuscript, “An RNA ...

Biotech company Deep Genomics has brought on B2B comms agency Fight or Flight to help build its communications function. The platform supports geneticists, molecular biologists, chemists, ...

One of the biggest challenges pharmaceutical companies face is with the time taken to discover new drugs, develop them and get them to market. This lengthy process is punctuated with false starts.

Deep learning—a form of artificial intelligence capable of improving itself with limited user input—has radically reshaped the landscape of biomedical research since its emergence in the early 2010s.

Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic medicines with its AI foundation model platform, today announced the appointment of respected business leaders Thong ...

Artificial intelligence (AI) machine learning is rapidly emerging as a powerful tool in the quest for novel diagnostics, therapies, and treatment for complex diseases such as cancer. Increasingly, ...

SAN FRANCISCO, Jan. 13, 2025 /PRNewswire/ -- Kerna Laboratories Inc, a San Francisco-based AI biotech startup, emerged from stealth with the launch of an AI platform for developing novel RNA-based ...

An international research team has developed a new genomic technique that can track the spread of multiple superbugs in a hospital simultaneously. In a proof-of-concept study, scientists at the ...